Calidi Biotherapeutics Inc (CLDI)
0.23
0.00 (0.00%)
USD |
NYAM |
May 15, 15:31
Calidi Biotherapeutics Enterprise Value: 8.942M for May 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 14, 2024 | 8.942M |
| May 13, 2024 | 8.814M |
| May 10, 2024 | 9.305M |
| May 09, 2024 | 9.163M |
| May 08, 2024 | 9.412M |
| May 07, 2024 | 8.974M |
| May 06, 2024 | 8.381M |
| May 03, 2024 | 7.919M |
| May 02, 2024 | 8.061M |
| May 01, 2024 | 7.777M |
| April 30, 2024 | 7.848M |
| April 29, 2024 | 8.310M |
| April 26, 2024 | 6.629M |
| April 25, 2024 | 6.604M |
| April 24, 2024 | 6.530M |
| April 23, 2024 | 6.853M |
| April 22, 2024 | 6.462M |
| April 19, 2024 | 6.675M |
| April 18, 2024 | 6.604M |
| April 17, 2024 | 7.848M |
| April 16, 2024 | 8.278M |
| April 15, 2024 | 22.24M |
| April 12, 2024 | 25.61M |
| April 11, 2024 | 23.65M |
| April 10, 2024 | 21.79M |
| Date | Value |
|---|---|
| April 09, 2024 | 22.85M |
| April 08, 2024 | 14.42M |
| April 05, 2024 | 14.99M |
| April 04, 2024 | 15.98M |
| April 03, 2024 | 18.33M |
| April 02, 2024 | 18.65M |
| April 01, 2024 | 20.57M |
| March 28, 2024 | 21.00M |
| March 27, 2024 | 21.09M |
| March 26, 2024 | 21.17M |
| March 25, 2024 | 21.74M |
| March 22, 2024 | 21.53M |
| March 21, 2024 | 22.28M |
| March 20, 2024 | 24.12M |
| March 19, 2024 | 22.75M |
| March 18, 2024 | 22.24M |
| March 15, 2024 | 23.56M |
| March 14, 2024 | 22.56M |
| March 13, 2024 | 23.31M |
| March 12, 2024 | 24.84M |
| March 11, 2024 | 22.70M |
| March 08, 2024 | 23.34M |
| March 07, 2024 | 25.58M |
| March 06, 2024 | 25.03M |
| March 05, 2024 | 28.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.462M
Minimum
Apr 22 2024
183.39M
Maximum
Sep 13 2023
51.74M
Average
46.35M
Median
Jan 17 2024
Enterprise Value Benchmarks
| Minerva Neurosciences Inc | -17.47M |
| Viking Therapeutics Inc | 7.031B |
| CytomX Therapeutics Inc | 0.8796M |
| Genprex Inc | -1.828M |
| Janux Therapeutics Inc | 1.832B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.229M |
| Total Expenses (Quarterly) | 9.208M |
| EPS Diluted (Quarterly) | -0.2317 |
| Earnings Yield | -320.3% |